<?xml version='1.0' encoding='utf-8'?>
<document id="23553423"><sentence text="Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions."><entity charOffset="0-10" id="DDI-PubMed.23553423.s1.e0" text="Telaprevir" /></sentence><sentence text="This article provides an unbiased review of the pharmacokinetic, pharmacodynamic, and drug-drug interaction data of telaprevir, an NS3/4A protease inhibitor"><entity charOffset="116-126" id="DDI-PubMed.23553423.s2.e0" text="telaprevir" /></sentence><sentence text=" Telaprevir is well absorbed with fatty food, moderately protein bound (59-76 %) with a large volume of distribution (~252 L), primarily metabolized by cytochrome P450 (CYP) 3A4 and P-glycoprotein, and is largely excreted into feces"><entity charOffset="1-11" id="DDI-PubMed.23553423.s3.e0" text="Telaprevir" /></sentence><sentence text=" Pharmacokinetic and pharmacodynamic parameters are well described in healthy subjects and individuals infected with hepatitis C virus (HCV), although only limited data are available in specific patient subpopulations" /><sentence text=" Telaprevir is recommended to be given at 750 mg by mouth every 8 h for 12 weeks, in combination with peginterferon and ribavirin (the standard care)"><entity charOffset="1-11" id="DDI-PubMed.23553423.s5.e0" text="Telaprevir" /><entity charOffset="120-129" id="DDI-PubMed.23553423.s5.e1" text="ribavirin" /><pair ddi="false" e1="DDI-PubMed.23553423.s5.e0" e2="DDI-PubMed.23553423.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23553423.s5.e0" e2="DDI-PubMed.23553423.s5.e1" /></sentence><sentence text=" The addition of telaprevir to the standard care regimen results in increased sustained virological response in treatment-naïve patients (30 %) and treatment-experienced patients (up to 50 %), and works synergistically to lower viral resistance"><entity charOffset="17-27" id="DDI-PubMed.23553423.s6.e0" text="telaprevir" /></sentence><sentence text=" Telaprevir is a substrate and/or inhibitor of CYP3A4 and P-glycoprotein, and drug-drug interaction studies in humans have focused on these pathways"><entity charOffset="1-11" id="DDI-PubMed.23553423.s7.e0" text="Telaprevir" /></sentence><sentence text=" Based on our analysis, a few reported drug-drug interactions may be classified as clinically significant, but more experiments under dosing conditions that resemble those given in the clinic are needed to understand the relevance of some of the reported interactions" /><sentence text=" Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic-pharmacodynamic relationships"><entity charOffset="73-83" id="DDI-PubMed.23553423.s9.e0" text="telaprevir" /></sentence><sentence text=" In vitro characterization of other phase 1-3 metabolic pathways could assist in elucidating the mechanisms of the drug-drug interactions observed in humans" /><sentence text=" " /></document>